A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

Aeglea BioTherapeutics

Status and phase: Terminated; Phase 3

Conditions: Hyperargininemia; Arginase I Deficiency

Treatments: Drug: Pegzilarginase

Study type: Interventional

Funder types: Industry

Identifiers

NCT05676853

CAEB1102-305

Details and patient eligibility

About

This is an open-label, multicenter study to evaluate the safety of weekly SC administration of pegzilarginase over 12 months in subjects with ARG1-D. The study consists of a screening period of up to 4 weeks, a subsequent 12-month treatment period, and a Safety Follow-Up Visit 2 weeks after the last treatment.

Full description

Open-label, multicenter study to evaluate the safety of weekly SC administration of pegzilarginase over 12 months in subjects with ARG1-D. The study consists of a screening period of up to 4 weeks, a subsequent 12-month treatment period, and a Safety Follow-Up Visit 2 weeks after the last treatment.

Enrollment: 3 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Prior enrollment in pegzilarginase clinical studies, with completion of treatment or continued dosing as of the study termination date
2. Written informed consent by subject/parent/legal guardian, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol
3. Negative pregnancy test within 7 days prior to dosing in childbearing subjects if they are sexually active
4. If the subject (male or female) is engaging in sexual activity that could lead to pregnancy, must be surgically sterile, post-menopausal (female), or must agree to use a highly effective method of birth control during the study and for a minimum of 30 days after the last study drug administration. Highly effective methods of contraception include combined (estrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation, progesterone-only hormonal contraception associated with inhibition of ovulation, intrauterine device, or intrauterine hormone-releasing system

Exclusion criteria

1. Subjects with acute or ongoing hyperammonemia within 6 weeks of the first dose
2. Subjects with medical conditions or underlying issues that, in the opinion of the Investigator, would preclude participation in the study

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3 participants in 1 patient group

Pegzilarginase

Experimental group

Description:

Weekly subcutaneous dosing of pegzilarginase plus individualized disease management for 52 weeks

Treatment:

Drug: Pegzilarginase